2021.03.16 Press release

--To the press -

FRONTEO begins joint research with L-Pixel

Combining natural language analysis AI and image analysis AI, aiming to develop new medical AI in the area of ​​dementia diagnosis support

FRONTEO Inc.
Masahiro Morimoto, President and CEO
東京 都 港区 港 南 2-12-23
(Code number: 2158 TSE Mothers)

 FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereafter FRONTEO) is L-Pixel Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, President: Yuki Shimahara, Tomihisa Kamada, hereafter L-Pixel) ), And started joint research toward the development of medical AI software in the area of ​​dementia diagnosis support.

 

 

 L-Pixel, which has strengths in image analysis in the life science field, has various technologies and products that utilize image analysis technology, such as AI image diagnosis support business and research, development, and sales of AI image analysis software that supports drug discovery. We are planning and developing. In October 2019, medical image analysis software "EIRL Brain Aneurysm" that automatically detects "cerebral aneurysm" from brain MRI images and supports doctors' diagnosis(1)Released in Japan.We have obtained the first regulatory approval in Japan as a program medical device in the field of brain MRI utilizing deep learning.

 

 On the other hand, FRONTEO has expertise in the life science field, business experience, and natural language analysis technology, and has strengths such as the paper search AI system "Amanogawa", the drug discovery support AI system "Cascade Eye", and the fall prediction AI system. We are developing and marketing various solutions that promote the digitization of drug discovery and medical care, such as "Coroban".In January 2021, we obtained a first-class medical device manufacturing and sales license, and if regulatory approval is obtained, we will be the world's first linguistic AI medical device "conversational dementia diagnosis support AI system." We are proceeding with the development and subsequent research and development of various language-based AI medical devices.

 

 In this collaboration, FRONTEO's natural language analysis AI and L-Pixel's image analysis AI technology will be combined to make it more versatile and practical in the medical field, starting with the dementia diagnosis support area, diagnosis, treatment, prevention, and monitoring. We aim to develop highly sophisticated AI software.

 

 In the medical and health fields, as in other fields, a huge amount of data is generated every day, but the value has not yet been fully demonstrated due to the lack of soil for data analysis. FRONTEO considers that a huge market for medical innovation is latent beyond the utilization of such unstructured data, and will continue to be equal to everyone through AI, including this collaboration with L-Pixel. We will make innovative proposals for the medical and drug discovery industries in order to deliver medical care and new medical value.

 

 The impact of this matter alone on FRONTEO's business results for the current fiscal year is minor, but we will promptly notify you if there are any matters to be disclosed.

 

(1) Approval number: 30100BZX00142000 Brand name: Medical image analysis software EIRL aneurysm

 

■ AI diagnostic imaging support technologyEIRLAbout (Aile)

URL : https://eirl.ai/ja/ (EIRL product site (for medical professionals))

With the increasing sophistication of modality, the work of medical imaging is enormous. We aim to provide an environment that enables efficient and accurate diagnosis by analyzing medical image information such as brain MRI and chest X-rays using a unique algorithm that utilizes AI.

 

■ About conversational dementia diagnosis support AI system 

URL:https://lifescience.fronteo.com/aidevice/dementia/

The conversational dementia diagnosis support AI system (AI medical device) uses FRONTEO's original natural language analysis AI "Concept Encoder (registered trademark: conceptencoder, reading: concept encoder)" between the patient and the doctor. It is a system that can screen for cognitive dysfunction from daily conversation for about 5 minutes.We believe that this system can contribute to the progress of digital medical care such as telemedicine and the efficiency and standardization of medical care, in addition to measures against dementia, which is an important issue in Japan, which is facing a super-aging society. I will. FRONTEO entered into a business alliance agreement with Kyowa Yakuhin Kogyo Co., Ltd., which aims to become a CNS (central nervous system) total solution company, in June 10, aiming for early commercialization and early market penetration in the medical field.Patent registration number: Patent No. 2020

 

■ About Concept Encoder

URL:https://lifescience.fronteo.com/technology/conceptencoder/

"Concept Encoder (registered trademark: concept encoder, reading: concept encoder)" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specially in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. "Concept Encoder" can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

 

■ About L-Pixel Co., Ltd. URL:https://lpixel.net/

L-Pixel Co., Ltd. has strengths in image analysis in the life science field, and has developed high-precision software that utilizes AI (artificial intelligence) in the medical, pharmaceutical, and agricultural fields. We are developing our business centered on the AI ​​image diagnosis support technology "EIRL" and the AI ​​image analysis solution "IMACEL" that supports drug discovery.

 

FRONTEO  URL:https://www.fronteo.com/

FRONTEO uses the in-house developed AI engine "KIBIT" and "concept encoder" specializing in natural language processing to extract meaningful and important information from a huge amount of text data to support corporate business. A data analysis company. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support international litigation of companies. Has been deployed.Based on the AI ​​technology cultivated in the legal tech business, we expanded the business field to the life science field, business intelligence field, and OSINT from 8, and created by using AI to "turn text data into knowledge". We contribute to solving various corporate issues such as drug support, dementia diagnosis support, financial, human resources, and sales support. Listed on TSE Mothers on June 2014, 2007. January 6, 26 Obtained a first-class medical device manufacturing and sales license (permit number: 2021B1X13).The capital is 13 thousand yen (as of March 1, 10350).

 

* FRONTEO, KIBIT, conceptencoder, and Coroban are registered trademarks of FRONTEO in Japan.

<Contact information for the press>

Public Relations Officer, FRONTEO Inc. Segawa

E-mail: pr_contact@fronteo.com

 

<Inquiries about Life Science AI Business>

FRONTEO Inc. Life Science AI Business Headquarters

https://lifescience.fronteo.com/contact

ja 日本語
Machine Translation by Google. : close x